v3.26.3
Schedule of Financial Information by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Net revenues $ 5,432 $ 5,736 $ 9,278 $ 17,162
Cost of revenues (excluding amortization of acquired intangible assets) 2,347 5,242 3,799 8,796
Direct expenses 6,968 15,986 19,127 33,976
Segment contribution (3,883) (15,492) (13,648) (25,610)
Indirect expenses 354 [1] 372 [1] 722 [2] 740 [2]
Loss from operations (4,237) (15,864) (14,370) (26,350)
Other income (expenses) 4,943 (8,660) 15,950 (17,928)
Net loss before income taxes 706 (24,524) 1,580 (44,278)
Cell Therapy [Member]        
Segment Reporting [Line Items]        
Net revenues 1,339 759 1,832 1,023
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses 1,808 2,927 4,275 6,184
Segment contribution (469) (2,168) (2,443) (5,161)
Biobanking [Member]        
Segment Reporting [Line Items]        
Net revenues 652 1,275 1,902 2,683
Cost of revenues (excluding amortization of acquired intangible assets) 227 220 449 429
Direct expenses 164 387 407 756
Segment contribution 261 668 1,046 1,498
Degenerative Disease [Member]        
Segment Reporting [Line Items]        
Net revenues 3,441 3,702 5,544 13,456
Cost of revenues (excluding amortization of acquired intangible assets) 2,120 5,022 3,350 8,367
Direct expenses 224 1,854 1,812 6,601
Segment contribution 1,097 (3,174) 382 (1,512)
Other [Member]        
Segment Reporting [Line Items]        
Net revenues
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses 4,772 10,818 12,633 20,435
Segment contribution $ (4,772) (10,818) (12,633) (20,435)
Indirect expenses   $ 372 [1] $ 722 [2] 740 [2]
Net loss before income taxes      
[1] Comprised of amortization of intangible assets.
[2] Comprised of amortization of intangible assets.